ISPOR 18th Annual European Congress7-11 November 2015, Milan, Italy

Join the IMS Health Symposium“Enriched real-world data (RWD) studies:Tapping into the growing use of patient-leveldata to optimize observational study designand execution”Meet the largest expert community in RWE – now including our new colleagues fromCegedim Strategic Data

Discover the findings from our latest research

IMS Health Real-World Evidence Solutionsat ISPOR, November 2015

2

IMS Health Our Distinctive Approach

IMS Health has taken a holistic approach to real-world evidence (RWE) in pursuit ofthe most robust and insightful views of patient outcomes. With the breadth and depthof our capabilities, we are uniquely positioned to generate and use RWE globally.

Applying the appropriate scientific and commercial lens and latest techniques to anonymous real-worlddata (RWD) is critical to realizing the value of RWE in healthcare decisions.

IMS Health Real-World Evidence Solutions

IMS Health can uniquely support all elements of the RWE ecosystem – an environment where all the components of RWE come together for a consistent, insightful view of whatreally happens in healthcare. An environment which, for thefirst time, helps all functions realize its potential.

Technology-EnabledAnalyticsReal-World

Data

Services and

Engagement

IMS HEALTHREAL-WORLD

EVIDENCESOLUTIONS

Acce

ss th

e ri

ght r

eal-w

orld

dat

a

Analyze the data

Create datasets

Apply the insights

Introducing the RWE ecosystem

Real-World DataIdentify and access the most appropriate data sources while ensuring patient privacy

• The broadest and deepest collection of scientifically-validated, anonymous patient-level data assets• Complement fit-for-purpose data by custom data sourcing to close data gaps

Technology-Enabled AnalyticsCreate consistent data models empowering analyses and leveraging innovative technologies

• Extraction, analysis and visualization of RWD with IMS Health’s E360TM technology suite • Sophisticated data linkage and interpretation

Services and EngagementAnalyze RWD using scientific rigor, clear governance and advanced analytic and processing capabilities

• Market Access & HTA• Health Economics• Outcomes Research• Pharmacoepidemiology & Drug Safety • Commercial Analytics

ISPOR 18th Annual European Congress, November 2015, Milan, Italy 3

Welcome to IMS Health at ISPOR Milan, 2015

Increased emphasis on RWE and a concentrated focus on patient benefits haveplaced outcomes research (OR) at the heart of healthcare decision making.

Reflecting its growing importance and potential is the need for more compelling, impactful OR acrossthe spectrum of evidence evaluation. Approaches that can extend existing RWD and accelerate itspower to answer critical questions are key to achieving this goal.

IMS Health is committed to innovation in data collection to overcome the limitations of traditionalmethods and drive richer insights and faster results. We look forward to sharing the research this hasenabled during the ISPOR 18th Annual European Congress as progress towards “closing the gap” inOR continues.

Please join us during the event. An overview of our activities can be found in this brochure.

We hope to see you in Milan!

#1 Partner of Choice for RWE

• Largest, international fit-for-purpose RWDportfolio available with 500+ million anonymouslongitudinal patient data records in 25+ markets

• Partnerships and data sourcing capabilities tobring clients data that is right for their needs

• 3,500+ publications building healthcare knowledge

• Leading edge technology and analytics toenhance understanding of patient outcomes,healthcare costs, pharmacoepidemiology, drugsafety and product value

• Experts in 20+ markets with deep specialism inRWE, HTA and payer requirements to translateinsights into actions

IMS Health is excited to announce that Cegedim Strategic Data has joined our Real-WorldEvidence Solutions team, boosting our RWD assets and analytical expertise and confirming ourrole as the partner of choice for RWE.

IMS Health Symposium Wednesday, 1 1 November

4IMS Health Real-World Evidence Solutions

“Enriched real-world data (RWD) studies: Tapping into the growing use of patient-level data to optimize observational study design and execution”Pharmaceutical manufacturers face a challenge in meeting increased demand for RWE throughprospective observational studies in a cost-effective and timely way. Although many are comfortablelooking purely to electronic patient data (eg, EMRs) for retrospective database analysis, they are notalways aware of how these sources can support primary data collection to generate the rich clinicaldata needed.

Enriched RWD studies – observational studies supplemented by de novo data collection – are one such alternative. These may include the use of technology embedded into an EMR system to promptfor additional variables to be collected during patient visits and/or site or patient randomization.Pragmatic trials with EMR follow-up can also be used to evaluate the impact of approaches toenhancing adherence, with modest expenditures compared to RCTs. In addition, data can be collecteddirectly from the patient, providing missing insights about their experience when relying onphysician-reported data alone.

This symposium will discuss these processes as well as applications for enriched RWD studies,including both for targeted use and for the creation of more enduring evidence platforms. We willshow how they can lead to more robust and efficient research, leveraging case studies to demonstratethe benefit for stakeholders.

Members of our global Real-World Evidence Solutions team will be on hand during ISPOR todiscuss your needs in RWE and explain how we can help you address them.

Come and see us at the IMS Health stand in the exhibition area (Nos 616, 617, 700, 701) todiscover more about our expertise and capabilities, which have recently expanded with theexciting addition of Cegedim Strategic Data.

Visit us at the IMS Health stand

IMS Health Symposium Agenda

IMS Health Symposium Chair

5ISPOR 18th Annual European Congress, November 2015, Milan, Italy

07:30–07:40

Introduction: RWE creating new approaches for observational researchAlison Bourke, MSc, MRPharm.S, FISPE, (Chair) Scientific Director, Real-World Evidence Solutions, IMS Health, UK

07:40–08:00

Next generation observational research: Enriched RWD studiesJoshua Hiller, MBA, Senior Principal, Real-World Evidence Solutions, IMS Health, UKPierre Engel, Pharm.D, MPH, PhD, Associate Director Epidemiology, Real-World & Late Phase Research, Quintiles, France

08:00–08:20

How to benefit from enriched RWD studies: Reflections from a study sponsor Andrew Shaw, BSc, PhD, RWE Alliance Director, AstraZeneca, UKLance Brannman, PhD, Group Director, Health Economics & Payer Analytics, AstraZeneca, USA; Member of theBoard, Centre for Health Economics, Gothenburg University, Sweden

08:20–08:30

Moderated Q&AAlison Bourke (Chair)

Proceedings from the symposium can be obtained from IMS Health. To receive a copy, please email Angelika Boucsein at Aboucsein@de.imshealth.com

Continental breakfast will be available for all symposium attendees

Alison Bourke, MSc, MRPharm.S, FISPE Alison Bourke is a Scientific Director, RWE Solutions at IMS Health. She has over 25 years of experience workingwith primary care patient data resources in the UK and a particular interest in their use to explore innovativescientific methodologies. Previously, Alison headed the research team at CSD Medical Research UK, providingprimary care data and support for a range of studies, including pharmacoepidemiology and health outcomesresearch. She pioneered innovative linking ‘pseudonymization at source’ technology and was instrumental insetting up the Health Improvement Network (THIN), bringing access to 12 million pseudonymized patientrecords. A trained pharmacist, Alison has also held roles at BMS where she analyzed one of the first computer-collected safety studies, and Cegedim INPS where she supported the successful launch of GPRD.

Continued overleaf...

IMS Health Real-World Evidence Solutions 6

IMS Health Symposium SpeakersJoshua Hiller, MBAJoshua Hiller is a Senior Principal, RWE Solutions at IMS Health, supporting the strategic planning anddevelopment of the company’s capabilities for data sourcing, integration, analytics and studies. He is alsocurrently serving as Alliance Director in IMS Health’s collaboration with AstraZeneca for the advancement ofRWE. During a career that includes roles in market analytics, government and healthcare consulting in both theUSA and UK, Joshua has led a wide range of projects for clients in the pharmaceutical and biotech sector as wellas industry associations. He has extensive experience in pharmaceutical pricing, contracting, market landscapedevelopment, supply management, cross border trade, lifecycle management, competitive defense, genericsmarket drivers and account management, with expertise across US and European markets.

Pierre Engel, Pharm.D, MPH, PhDDr. Pierre Engel is Associate Director Epidemiology, Real-World & Late Phase Research at Quintiles, France,managing a team of epidemiologists involved mainly in Post Authorisation Safety Studies (PASS). He has eightyears of experience in international observational research including roles as Epidemiologist at a medium-sizeCRO and at INSERM where he was in charge of developing epidemiological studies on existing data in women’shealth. Pierre has strong expertise in the design, scientific oversight, analysis and reporting of observationalstudies as well as epidemiology methods, CER, pharmacoepidemiology, and database research. He is a memberof both the Steering Group and HTA Working Group at ENCePP, is actively involved as an epidemiologist onmany large international programs, and has designed numerous PASS endorsed by the EMA’sPharmacovigilance Risk Assessment Committee.

Andrew Shaw, BSc, PhDDr. Andy Shaw is RWE Alliance Director at AstraZeneca, UK, where he focuses on continuing to develop thecompany’s RWE capabilities globally, particularly in the respiratory and oncology therapeutic areas. He hasestablished and maintained strong partnerships with many external stakeholders, including IMS Health andQuintiles. Andy began his career as a lecturer at the University of London before moving into the pharmaceuticalindustry. He has more than 18 years of experience at AstraZeneca, both in the UK and for a time in Japan, inpositions that have primarily focused on generating clinical data for regulatory submissions. More recently,during the last 4-5 years, Andy’s focus has shifted to generating evidence outside of clinical trial settings for amultitude of purposes.

Lance Brannman, PhDDr. Lance Brannman is Group Director, Health Economics & Payer Analytics for respiratory, inflammation andautoimmune diseases at AstraZeneca, USA. He was previously responsible for cardiovascular & metabolicdiseases, CNS diseases and infection, with accountability in both roles for delivering global health economicsprojects. He is also a Member of the Board at the Centre for Health Economics, Gothenburg University, Sweden.Lance spent several years as an academic before joining the pharmaceutical industry where he has held varioussenior-level positions in health economics and outcomes research at AstraZeneca and Novo Nordisk A/S. He hasextensive experience in pharmacoeconomics spanning modeling, technical writing, RWE, clinical trial design andPRO administration, as well as expertise in microeconomic analysis, statistics & econometrics, and programming.

ISPOR 18th Annual European Congress, November 2015, Milan, Italy 7

Live Sessions with IMS Health

Book a demonstration of IMS Health’s E360™ technology suiteIMS Health RWE experts will be running demonstrations of our powerful E360™ data platform technology and applications suite which allowsresearchers to answer all questions – from the routine to the most challenging –in a standardized, intuitive way.

Schedule your individual presentation at the IMS Health stand or by emailing Peter Riebel at Priebel@de.imshealth.com

Issue Panel• The cost of no Europe - Localized or centralized assessment of relative efficacy

– 10 November, 13:45–14:45

Workshops• Evidence synthesis in HTA decision making – 10 November, 08:45–09:45• Network meta analysis modeling for dose response and class effects

– 11 November, 15:00–16:00

Research Podiums• Hospital cost and length of stay in chronic heart failure

– 9 November, 16:15–16:30• Cost-effectiveness in COPD – 9 November, 16:30–16:45

See pages 8–11 for further details.

9 NOV CV3 THE COST AND LENGTH OF STAY OF HOSPITAL EMERGENCY DEPARTMENT

VISITS FOR CHRONIC HEART FAILURE PATIENTS IN CANADAFischer AA, Liu N, Borelli R, Zaour N,Barbeau M

ResearchPodium

CE4

ASSESSING THE COST-EFFECTIVENESS OF USING ACLIDINIUM BROMIDE 400 µG /FORMOTEROL FUMARATE DIHYDRATE 12 µG COMPARED TO ACLIDINIUMBROMIDE 400 µG IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONICOBSTRUCTIVE PULMONARY DISEASE

Ramos M, Haughney J, Henry N,Lindner L, Lamotte M

ResearchPodium

PCV53 CARDIOVASCULAR EVENT RATES IN A HIGH-RISK GENERAL POPULATIONCOHORT OF 340,000 INDIVIDUALS IN THE UNITED KINGDOM

Ansell D, Khan I, Proudfoot C,Gbenedio T, Joulain F, Pockett RD,Catterick D, Gooch K

ResearchPoster

PCV63 AN ASSESMENT OF ENOXAPARINE BENEFIT ON HEALTHCARE BUDGET IN SPAIN Delgado M, Restovic G, Planellas L,Rubio M, Miñarro C

ResearchPoster

PCV67MEDICAL COST OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF)AND TREATED WITH VITAMIN K ANTAGONISTS (VKAS) ACCORDING TO INRCONTROL STATUS IN SPAIN

Postema R, Bardoulat I, Roset M,Maurel F, Lefevre C, Evans D

ResearchPoster

PCV85

AN EPIDEMIOLOGICAL EVALUATION OF THE INCIDENCE OF DEEP VENOUSTHROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH HIP OR KNEEREPLACEMENT SURGERY AND OF ITS IMPACT ON THE AVERAGE LENGTH OFSTAY AND HOSPITALIZATION COST

Chevalier P, Lamotte M ResearchPoster

PCV89 A COMPARISON OF TWO LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) INTERMS OF COST PER PATIENT

Planellas L, Miñarro C, Restovic G,Delgado M, Rubio M

ResearchPoster

PCV90 THE COST OF ACUTE CARE HOSPITALIZATIONS ASSOCIATED WITH CHRONICHEART FAILURE IN CANADA

Fischer AA, Liu N, Borelli R, Barbeau M, Zaour N

ResearchPoster

PCV91AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUSCORONARY INTERVENTIONS ON THE HOSPITALIZATION COST, LENGTH OF STAYAND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES

Chevalier P, Lamotte M ResearchPoster

PCV169 THE ECONOMIC BURDEN OF POOR ADHERENCE TO STATINS IN BELGIUM Ramos M, Caekelbergh K, Lamotte M ResearchPoster

PMH2 RISK FACTORS FOR DEMENTIA DIAGNOSIS IN GERMAN PRIMARY CAREPRACTICES

Wendschlag A, Jacob L, Kostev K,Bohlken J, Rapp MA

ResearchPoster

PMH3 COGNITIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER AND THEIR ITALIANPSYCHIATRISTS' PERCEPTION

Pegoraro V, Cataldo N, Albert U,Brugnoli R, Caraci F, Dell'Osso BM, Di Sciascio G, Tortorella A, Vampini C

ResearchPoster

PMH7

TREATMENT CONTINUATION AND TREATMENT CHARACTERISTICS OF FOURLONG ACTING ANTIPSYCHOTIC MEDICATIONS (PALIPERIDONE PALMITATE,RISPERIDONE MICROSPHERES, OLANZAPINE PAMOATE AND HALOPERIDOLDECANOATE) IN THE NETHERLANDS

Denee TR, Geerts P, Sermon J,Decuypere F, Widrich C, Rijntjes R,Mulder CL

ResearchPoster

PMH45 DRUG UTILIZATION PATTERN OF LISDEXAMFETAMINE DIMESYLATE IN EUROPE Cook MN, Varughese S, Maxwell T,Thun B, Ehlken B, von Bredow D, Keja J

ResearchPoster

PMH48 THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS INBELGIUM: PRESCRIBING BEHAVIOR AND MISUSE OF ANTIDEPRESSANTS

Ramos M, Brouyère S, Caekelbergh K, Lamotte M

ResearchPoster

PMH49 THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS INBELGIUM Caekelbergh K, Ramos M, Lamotte M Research

Poster

PSS26INTRAVITRAEL AFLIBERCEPT INJECTION FOR THE TREATMENT OF VISUALIMPAIRMENT DUE TO MACULAR OEDEMA SECONDARY TO BRANCH RETINALVEIN OCCLUSION: COST-EFFECTIVENESS VERSUS RANIBIZUMAB

Lovato E, Lloyd A, Wilson B, Wittrup-Jensen KU

ResearchPoster

8

IMS Health Activities 9 NovemberCODE TOPIC PRESENTERS TYPE

IMS Health Real-World Evidence Solutions

9

IMS Health Activities 9 & 10 November

ISPOR 18th Annual European Congress, November 2015, Milan, Italy

CODE TOPIC PRESENTERS TYPE

9 NOV

10 NOV

PCN10 PREVALENCE OF DEPRESSION AND ANXIETY AND THEIR RISK FACTORS INWOMEN WITH BREAST CANCER IN GERMAN PRIMARY CARE Engelhard J, Bleicher L, Kostev K Research

Poster

PCN13 THERAPY OF DEPRESSION IN CANCER AND NON-CANCER PATIENTS IN GERMANNEUROPSYCHIATRIC PRACTICES Ziegelbauer K, Engelhard J, Kostev K Research

Poster

PCN34A DESCRIPTION OF REAL-WORLD TREATMENT WITH ABIRATERONE ACETATE INMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN THEPOST-CHEMOTHERAPY SETTING IN FRANCE AND THE NETHERLANDS

Dearden L, Musingarimi P, Shalet N,Demuth D, Garcia Alvarez L,Muthutantri A, Venerus A, Lasry R,Hankins M, Maher T

ResearchPoster

PCN115 THE ANALYSIS OF INPATIENTS COST OF BREAST CANCER IN CHINA, 2011 Song S, Wang Z, Zhang M ResearchPoster

PCN123 ESTIMATION OF DIRECT MEDICAL COSTS ASSOCIATED WITH TREATMENT OFMETASTATIC MELANOMA IN SWITZERLAND

Christoffersen P, Khan N, Lucas J,Christodoulopoulou A, Del Ponte A,Gutzwiller F

ResearchPoster

PCN233 CANCER IS ASSOCIATED WITH INTRAOPERATIVE AND POSTPROCEDURALCOMPLICATIONS AND DISORDERS Engelhard J, Jockwig A, Kostev K Research

Poster

PCN277 THE ITALIAN REGIONAL ACCESS OF NEW CANCER DRUGS: AN EXAMPLE IN FOUR REGIONS Visentin E, Heiman F, Ripellino C Research

Poster

PCN319 4+ YEARS OF AMNOG – CLINICAL DRIVERS FOR SUCCESSFUL DOSSIERSUBMISSIONS IN ONCOLOGY Dehnen J, Goldhagen K, Petry D Research

Poster

PCN353 CURRENT TREATMENT PATTERNS IN PATIENTS WITH METASTATIC MELANOMA: ARETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES (US)

Chen Y, Ma Q, Hines DM, Zhao Z,Munakata J, Barber BL

ResearchPoster

PHP47 A COMPARISON OF TIME TO LAUNCH AND REIMBURSEMENT FOR NEWMEDICINES ACROSS DEVELOPED COUNTRIES

Hickson SS, Skinner B, Bosnic N,Smith A, Zhang Y, Millson B

ResearchPoster

PHP100 APPRAISING THE COST OF PHYSICIAN VISITS AND TECHNICAL PROCEDURES INFRANCE IN THE AGE OF OPEN DATA Sherwood A, Maurel F, Colin X Research

Poster

PHP132 THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIBIOTICS IN BELGIUM Caekelbergh K, Ramos M, Lamotte M ResearchPoster

PHP136 AVOIDABLE HOSPITALIZATIONS DUE TO MEDICATION ERRORS IN BELGIUM Ramos M, Caekelbergh K, Lamotte M ResearchPoster

PHP139 LISTE-EN-SUS REFORM IN FRANCE - WHAT ARE THE CONSEQUENCES? Mitrano M, Flostrand S ResearchPoster

PHP176ITALIAN LAW 326/2003 FOR THE REIMBURSEMENT OF ORPHAN AND LIFE SAVINGDRUGS AWAITING MARKET ENTRY: APPROVALS, REJECTIONS AND METHODS INAIFA'S EVALUATION PROCESS BETWEEN JANUARY 2013 AND MAY 2015

Prada M, Bertozzi C, Proietti B,Urbinati D

ResearchPoster

PHP215FROM CENTRALIZED MARKETING AUTHORIZATION TO NATIONALREIMBURSEMENT – A CHALLENGING JOURNEY FOR NEW MEDICAL PRODUCTSWITH PLACEBO CONTROLLED TRIALS

Eheberg D, Paulus G, Dannemann S,Batscheider A

ResearchPoster

PHP220 MANAGED ENTRY AGREEMENTS IN THE ITALIAN MARKET BETWEEN JUNE 2005AND JUNE 2015 Tettamanti A, Urbinati D, Noble M Research

Poster

PHP260 DOES CONDITIONAL MARKETING AUTHORISATION INFLUENCE MARKET ACCESSIN FRANCE, ENGLAND, AND GERMANY? Kaaniche A, Troubat A, Sherwood A Research

Poster

PHP324 REFORMING DRUG PRICING AND PATIENT ACCESS SYSTEMS TO SUPPORTUNIVERSAL COVERAGE IN DEVELOPING COUNTRIES Shankar R, Hickson SS Research

Poster

IMS Health Real-World Evidence Solutions 10

IMS Health Activities 10 & 11 NovemberCODE TOPIC PRESENTERS TYPE

10 NOV

11 NOV

PIN9PUBLIC HEALTH OUTCOMES OF PAEDIATRIC INFLUENZA VACCINATION WITH ANINTRANASAL TETRAVALENT LIVE ATTENUATED VACCINE IN BELGIUM USING ADYNAMIC TRANSMISSION MODEL

Gerlier L, Lamotte M, Dos SantosMendes S, Schwehm M, Eichner M

ResearchPoster

PDB13 A CROSS-SECTIONAL STUDY ON INSULIN TREATMENTS AND GLYCEMICCONTROL IN TYPE 2 DIABETES IN FRANCE, ITALY, GERMANY, UK AND SPAIN Phan T, Boutmy E, Coulombel N Research

Poster

PDB16 CARDIOVASCULAR OUTCOMES OF ANTIDIABETIC THERAPY - RESULTS OF ALITERATURE SEARCH

Greiner R, Eheberg D, Paulus G,Batscheider A

ResearchPoster

PDB40 HOSPITALIZATION COST AND LENGTH OF STAY ASSOCIATED WITHOPHTHALMOLOGICAL SURGERY DEPENDING ON THE DIABETIC STATUS Chevalier P, Lamotte M Research

Poster

PDB56 COST-EFFECTIVENESS OF DULAGLUTIDE 1.5MG ONCE WEEKLY FOR THETREATMENT OF PATIENTS WITH TYPE TWO DIABETES MELLITUS IN SWEDEN

Raibouaa A, Borgeke H, Alexiou D,Lowin J, Norrbacka K

ResearchPoster

PMS3 INCREASED RISK OF OSTEOPOROSIS IN DEPRESSED PATIENTS: A REAL-WORLDDATA STUDY CONDUCTED IN ITALY

Heiman F, Moretti R, Pegoraro V,Cataldo N

ResearchPoster

PMS7 REDUCTION IN C-REACTIVE PROTEIN WITH BIOLOGIC DRUGS IN RHEUMATOIDARTHRITIS AND SPONDYLITIS PATIENTS IN GERMAN RHEUMATOLOGIST PRACTICES Gossen N, Kostev K Research

Poster

PMS68BIOLOGICAL AGENTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO HADFAILED TREATMENT WITH METHOTREXATE IN THE SPANISH CLINICAL SETTING: A COST-EFFECTIVENESS ANALYSIS

Sánchez R, Restovic G, Planellas L ResearchPoster

PMS90 DISPENSING FREQUENCY AMONG PATIENTS WITH RHEUMATOID ARTHRITISTREATED WITH RITUXIMAB IN ENGLAND Tsoumani E, McCann E, Tham R, Yu E Research

Poster

PSY5 HOW ARE PAIN TREATMENT RESPONSE RATES IN PRIMARY CARE INFLUENCED BY CO-PRESCRIPTION OF CYP2D6 INHIBITORS?

Pockett RD, O'Leary CJ, Anderson P,Nasser A, Winfield TG, Ansell D

ResearchPoster

PSY45 THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013MIDAS SALES DATA ANALYSIS

Divino V, DeKoven M, Kim T, Kleinrock M, Wade RL, Kaura S

ResearchPoster

PSY51 ASSESSING THE BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS IN BELGIUMUSING A LONGITUDINAL HOSPITAL DATABASE Gerlier L, Lamotte M, Chevalier P Research

Poster

PSY98 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SPLENECTOMIZED IMMUNETHROMBOCYTOPENIA (ITP) PATIENTS – A TARGETED LITERATURE REVIEW Lebioda A, Batscheider A Research

Poster

PSY124 THE ITALIAN 648/96 LIST: APPROVALS, REJECTIONS AND METHODS IN AIFA'SEVALUATION PROCESS BETWEEN JANUARY 2013 AND MAY 2015

Prada M, Bertozzi C, Proietti B, Urbinati D

ResearchPoster

IP8 THE COST OF NO EUROPE: ARE THERE COSTS AND CONSEQUENCES OFLOCALIZED OR CENTRALIZED ASSESSMENT OF RELATIVE EFFICACY?

Kent A, Rappagliosi A, Longson C,Keja J Issue Panel

W8 EVIDENCE SYNTHESIS BASED ON AGGREGATE AND INDIVIDUAL-LEVEL DATA:CONSIDERATIONS FOR USE IN HTA DECISION MAKING

Reason T, Saramago Goncalves P,Asukai Y, Abrams KR Workshop

ENRICHED REAL-WORLD DATA (RWD) STUDIES: TAPPING INTO THE GROWING USE OF PATIENT-LEVEL DATA TO OPTIMIZE OBSERVATIONAL STUDY DESIGN AND EXECUTION

Bourke A, Hiller J, Engel P, Shaw A,Brannman L

EducationalSymposium

W31 NETWORK META ANALYSIS MODELS FOR DOSE-RESPONSE AND CLASS EFFECTSIN DECISION MAKING

Owen RK, Thorlund K, Mawdsley D,Reason T Workshop

PRM69PATIENT HETEROGENEITY IN COST-EFFECTIVENESS MODELS FOR CHRONICOBSTRUCTIVE PULMONARY DISEASE (COPD): ARE CURRENT MODELS SUITABLETO EVALUATE PERSONALIZED MEDICINE

Hoogendoorn M, Feenstra T, Asukai Y,Briggs A, Borg S, dal Negro R, Hansen RN,Jansson S, Wacker M, Risebrough N,Samyshkin Y, Leidl R, Rutten van-Mölken M

ResearchPoster

PRM72 CONTRASTING PREDICTIONS OF CARDIOVASCULAR INCIDENCE DERIVED FROMALTERNATIVE RISK PREDICTION MODELS IN TYPE 1 DIABETES McEwan P, Foos V, Lamotte M Research

Poster

ISPOR 18th Annual European Congress, November 2015, Milan, Italy 1111

IMS Health Activities 11 NovemberCODE TOPIC PRESENTERS TYPE

11 NOV PRM74

CONTRASTING MODEL PREDICTED LIFE EXPECTANCY IN PATIENTS WITH TYPE 2DIABETES ACROSS DIFFERENT MORTALITY RISK PREDICTION MODELS VERSUSDATA FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM

McEwan P, Foos V, Lamotte M ResearchPoster

PRM84THE IMPORTANCE OF ACCOUNTING FOR BASELINE HYPOGLYCAEMIAFREQUENCY WHEN MODELLING HYPOGLYCAEMIA DISUTILITY IN TYPE 1DIABETES MELLITUS

McEwan P, Lamotte M, Foos V ResearchPoster

PRM85 VALIDATING APPROACHES TO MODELLING END-STAGE RENAL DISEASE USINGTHE IMS CORE DIABETES MODEL McEwan P, Foos V, Lamotte M Research

Poster

PRM88 THE IMPACT OF BASELINE HBA1C AND HBA1C TRAJECTORIES ON TIME TOTHERAPY ESCALATION IN TYPE 2 DIABETES MELLITUS McEwan P, Foos V, Lamotte M Research

Poster

PRM98INVESTIGATING THE IMPACT OF CONTEMPORARY RISK FACTORS FOR DIABETESCOMPLICATIONS AND THEIR EVOLUTION ON RISK PREDICTION USING THEUKPDS 82 EQUATIONS

McEwan P, Foos V, Lamotte M ResearchPoster

PRM111 THE ROLE OF PATIENT-LEVEL DATA IN ASSESSING HEALTH ECONOMIC VALUE: ACASE STUDY USING EDGE AND THE CORE DIABETES MODEL

Foos V, McEwan P, Evans M,Paldanius P

ResearchPoster

PRM130USING MACHINE LEARNING TO DETECT PATIENTS WITH UNDIAGNOSED RAREDISEASES: AN APPLICATION OF SUPPORT VECTOR MACHINES TO A RAREONCOLOGY DISEASE

Rigg J, Lodhi H, Nasuti P ResearchPoster

PRM228SYSTEMATIC LITERATURE REVIEW OF ADJUNCTIVE ANTI-EPILEPTIC DRUG TRIALS IN PATIENTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURESILLUSTRATES CHANGES IN STANDARD OF CARE OVER 12-20 YEARS

Tsong WH, Gomez-Ulloa D, Li H,Forsythe A, Kramer L

ResearchPoster

PRM246NORDIC LONGITUDINAL DATA FROM ELECTRONIC MEDICAL RECORDS AND FULL POPULATION NATIONAL REGISTERS: UNIQUE OPPORTUNITIES FOR NEWINSIGHTS IN BENEFIT OF DIABETES PATIENTS

Lindh A, Persson F, Sobocki P,Bodegard J, Lindarck N

ResearchPoster

PRM250 FILLING THE GAP BETWEEN RISK/BENEFIT ASSESSMENT FOR DRUGS AND RISKASSESSMENT FOR CONSUMER GOODS Hofmann-Xu L, Bonduelle D, Plantör S Research

Poster

PRM264VALIDATION OF SOCIAL MEDIA ANALYSIS FOR OUTCOMES RESEARCH:IDENTIFICATION OF DRIVERS OF SWITCHES BETWEEN ORAL AND INJECTABLETHERAPIES FOR MULTIPLE SCLEROSIS

Risson V, Saini D, Bonzani I, Huisman A, Olson M

ResearchPoster

PIH18 A COST-EFFECTIVENESS EVALUATION COMPARING BIOSIMILAR BEMFOLA TOGONAL-F FOR THE TREATMENT OF INFERTILITY IN AN ITALIAN CONTEXT

Ripellino C, Visentin E, Gizzo S,Bühler K

ResearchPoster

PND41 COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATEFOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN

Gasche D, Restovic G, Casado V,Ramírez-Boix P, Martínez Lopez J

ResearchPoster

PND66COMPARISON OF COMPLIANCE AND DISCONTINUATION RATES AMONG MSPATIENTS TREATED WITH FINGOLIMOD AND OTHER DISEASE-MODIFYINGTHERAPIES: A CANADIAN RETROSPECTIVE CLAIMS ANALYSIS

Haddad P, Duquette P, Yeung M,Lamarche A, Fraelic A, Chan S

ResearchPoster

Seeking a new challenge?We are currently looking for exceptional, talented individuals at all levels globally to join ourinternational Real-World Evidence Solutions team. Please ask at the IMS Health stand during ISPOR oremail our global talent acquisition manager at RWESrecruiting@imshealth.com for further information.

©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

ORB01324

IMS Health Real-World Evidence Solutionsis based in 20 countries worldwide with regional headquarters in

RWEinfo@imshealth.comwww.imshealth.com/rwe

Europe210 Pentonville RoadLondon N1 9JYUnited KingdomTel: +44 (0) 20 3075 4800

The AmericasOne IMS DrivePlymouth Meeting Pennsylvania 19462USATel: +1 (484) 567 6461

Latin AmericaInsurgentes Sur # 2375 5th FloorCol. TizapanMéxico D.F.- C.P. 01090México Tel: +52 55 5089 5205

Asia Pacific & Japan8 Cross Street #21-01/02/03Singapore 048424SingaporeTel: +65 6412 7365

Toranomon Towers Office4-1-28 ToranomonMinato-ku Tokyo 150-0001JapanTel: +81 3 5425 9541

IMS Health Real-World Evidence Solutions Bibliography

Our research expertise and therapy area knowledge are captured inmore than 3,500 publications, spanning virtually all therapy areas andprojects completed in over 50 countries worldwide.

Pick up a copy of the latest IMS Health Real-World Evidence Solutions Bibliographyof published papers and presentations (2013-2015) incorporating publications fromCegedim Strategic Data, now part of IMS Health, from our stand at ISPOR or visitwww.imsrwebibliography.com to explore our database online.